Form 4: Kymera Therapeutics Director Felix Baker Granted 16,000 Stock Options by Board

Kymera Therapeutics, Inc. director Felix J. Baker was granted 16,000 non-qualified stock options with an exercise price of $46.47 per share, vesting over one year or by the next annual meeting.

Summary

• Felix J. Baker, a director of Kymera Therapeutics, Inc. (KYMR) and a managing member of Baker Bros. Advisors (GP) LLC, was granted 16,000 non-qualified stock options.
• The stock options have an exercise price of $46.47 per share.
• These options were granted under the Issuer's 2020 Stock Option and Incentive Plan.
• The options vest on the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the next annual meeting of stockholders, contingent on Felix J. Baker's continued service on the board.
• The options expire on June 24, 2035.
• Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. and 667, L.P.
• Per Baker Bros. Advisors LP policies, Felix J. Baker does not directly receive pecuniary interest from these securities; the Funds (Baker Brothers Life Sciences, L.P. and 667, L.P.) are entitled to it.
• Baker Bros. Advisors LP has voting and dispositive power over these stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a routine compensation event, it indicates continued alignment of a significant investor (Baker Bros.) with the company's long-term prospects through equity incentives for their representative on the board.

Positives

• The grant of stock options to a director aligns management and board interests with shareholder interests, as the options gain value if the stock price increases.
• The long expiration date (June 24, 2035) provides a significant window for potential value realization.

Negatives

• No explicit negatives are detailed in this Form 4 filing, as it reports a routine compensation grant.

Risks

• The vesting of the stock options is subject to Felix J. Baker's continued service on the board of directors, meaning the options could be forfeited if his service ceases before vesting.
• The value of the stock options is dependent on the future market price of Kymera Therapeutics, Inc. common stock; if the stock price does not exceed the exercise price of $46.47, the options may expire worthless.

Future Outlook

This Form 4 filing primarily reports a past transaction (stock option grant) and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule of the options.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries for executive and board compensation, aiming to align the interests of leadership with long-term shareholder value. Baker Bros. Advisors is a prominent investor in the life sciences sector, and their director's compensation structure at Kymera Therapeutics is consistent with typical governance practices for companies backed by such investment firms.

Corporate Governance

Related Party Transactions

• The stock option grant to Felix J. Baker, a director, is considered a related party transaction given his role as a managing member of Baker Bros. Advisors (GP) LLC, which advises and manages funds (Baker Brothers Life Sciences, L.P. and 667, L.P.) that are significant shareholders and are the ultimate pecuniary beneficiaries of these options.
• Felix J. Baker and Julian C. Baker, through their ownership interests in the general partners of the Funds, may be deemed to have an indirect pecuniary interest in the stock options, even though the direct pecuniary interest flows to the Funds.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a key director and significant institutional investor (Baker Bros.) with long-term shareholder value, as the options gain value only if the stock price increases. This could be seen as a positive signal of continued commitment.
• Employees: No direct impact on general employees is mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned.

Next Steps

• The stock options will vest on the earlier of June 25, 2026, or the date of the next annual meeting of stockholders, subject to Felix J. Baker's continued service.
• Felix J. Baker or the beneficial owners (the Funds) may exercise the options at any time after vesting and before the expiration date of June 24, 2035.

Key Dates

Keywords

Kymera Therapeutics, KYMR, SEC Form 4, Stock Options, Insider Trading, Director Compensation, Baker Bros. Advisors, Equity Grant, Biotechnology, Pharmaceuticals